Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa
Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa https://www.eyevensys.com/wp-content/uploads/2018/08/pang-yuhao-OPwYu6nhWFc-unsplash-1.jpg 1920 1080 Eyevensys https://www.eyevensys.com/wp-content/uploads/2018/08/pang-yuhao-OPwYu6nhWFc-unsplash-1.jpgParis, France, and Cambridge, Mass., United States, October 05, 2020 – Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies…